Michael J. Farrell, Chairman and CEO of ResMed Inc., filed a Form 4 on September 9, 2026, reporting the exercise of stock options and a same-day sale of common stock that occurred on September 8, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Farrell exercised 4,991 ResMed common stock options at an exercise price of $146.34 per share on September 8, 2026.
- Shares sold: 4,991 shares of ResMed common stock were disposed of at a weighted average sale price of $222.4385 per share, with individual trade prices ranging from $220.680 to $225.390.
- Direct ownership after transactions: Farrell directly holds 466,256 shares of ResMed common stock following the reported transactions.
- Indirect ownership: An additional 2,090 shares are held indirectly through the Lisette and Michael Farrell Family Trust.
- Remaining options: Farrell beneficially owns 9,984 ResMed common stock options directly after the reported transactions, with an expiration date of November 21, 2026.
- 10b5-1 plan: The transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024.
ResMed CEO's Option Exercise and Share Sale on September 8, 2026
According to the Form 4 filed with the U.S. Securities and Exchange Commission, Michael J. Farrell, who serves as Chairman and CEO of ResMed Inc. (NYSE:RMD), executed two transactions on September 8, 2026. First, he exercised 4,991 stock options at a conversion price of $146.34 per share, with the options having first become exercisable on November 11, 2020, and vesting at a rate of one-third per year. The expiration date of those options is November 21, 2026.
On the same date, the filing discloses that 4,991 shares were sold at a weighted average price of $222.4385 per share. The filing notes that the sale was executed in multiple trades at prices ranging from $220.680 to $225.390. Following these two transactions, Farrell directly held 466,256 shares of ResMed common stock. He also holds 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust, and retains 9,984 stock options on a direct basis.
Both the option exercise and the share sale were reported as conducted pursuant to a Rule 10b5-1 plan that Farrell adopted on October 31, 2024, as noted in the filing's explanation of responses. The Form 4 was signed by Michael J. Farrell on September 9, 2026, and designates him as both a Director and an Officer in his role as Chairman and CEO.
What Was Disclosed
The filing reports a same-day option exercise and share sale by ResMed's Chairman and CEO on September 8, 2026, conducted under a pre-established 10b5-1 plan, resulting in direct beneficial ownership of 466,256 shares and 9,984 remaining options.



Please wait processing your request...